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Abstract
Background: At least 28 loci have been linked to autosomal dominant spinocerebellar ataxia (ADCA). Causative genes have been cloned for ten nucleotide repeat expansions (SCA1, 2, 3, 6, 7, 8, 10, 12, 17 , and 31) and six genes with classical mutations (SCA5, 13, 14, 15/16, 27, adn 28). Recently, a large British pedigree linked to SCA11 has been reported to carry a mutation in the TTBK2-gene. In order to assess the prevalence and phenotypic spectrum of SCA11, we screened 148 index patients of predominantly German (n=69) and French (n=79) descents with ADCA tested negative for a panel of SCA mutations (SCA1, 2, 3, 6, 7, and 17), for mutations in TTBK2.
Methods:
In the German ADCA cohort the complete coding sequence of the TTBK2-gene was PCR-amplified and screened for mutations by high-resolution-melting (HRM) analysis.
In the French cohort, exons known to carry mutations were directly sequenced. For both cohorts, the gene-dosage alterations were assessed using a customized multiplex ligation probe amplification (MLPA) assay.
Results:
In two of 148 ADCA families -one German and one French -we identified a potentially disease-causing SCA11 mutation. Interestingly, both carried an identical two basepair deletion (c.1306_1307delGA, p.D435fs448X in exon 12) leading to a premature stop codon. Gene dosage alterations were not detected in the TTBK2-gene. Clinically, our SCA11 patients had phenotypic characteristics as described before presenting with slowly progressive almost pure cerebellar ataxia with normal life expectancy.
Conclusion: SCA11 presented as ADCA III according to Harding's classification and is a rare cause of spinocerebellar ataxia in Caucasians accounting for less than 1% of dominant ataxias in central Europe.
Introduction
Genetic research elucidated disease-causing mutations in 18 subtypes of autosomal-dominant cerebellar ataxia (ADCA), classified as spinocerebellar ataxias (SCA) 1 . The concept of dynamic mutations leading to neurodegeneration in SCA was substantiated by repeat expansion mutations in SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10, SCA12, SCA17, and SCA31 2;3 . As one learned from PRKCG dysfunction (SCA14) 4 , the aetiology of SCAs goes beyond polyglutamine toxicity, and recently, non-dynamic or classical disease-causing mutations have furthermore been described for SCA5 (SPTBN2) 5 , SCA13 (KCNC3) 6 , SCA15/SCA16 (ITPR1) 7 , SCA20 (duplication at chromosome 11q12.2-11q12.3) 8 , SCA27
(FGF14) 9 , and SCA28 (AFG3L2) 10 , respectively.
SCAs are rare: prevalence studies in European region to date gave estimates range between 0.9 and 3/100.000 11 . The chance of familial cases to be diagnosed genetically depends on the ethnic origin of the family 3 . In western and central Europe 50% up to 80% of SCA patients with affected first degree relatives carry a disease causing mutation in the SCA genes identified so far 12;13 .
Recently, tau tubulin kinase 2 (TTBK2) has been implicated as the disease gene for SCA11 14 .
SCA11 has originally been described in a large British family and a smaller Pakistani family as rather slowly progressing, pure cerebellar ataxia. Although little is known about brain specific functions of TTBK2, inactivating mutations C-terminal of the serine/threonine protein kinase domain have been identified in these kindreds.
However, pathogenic TTBK2 mutations have not been identified in two series of ADCA patients (dHPLC mutation screening in 68 Han Chinese patients 15 and complete resequencing of all coding exons in 49 Caucasian patients 16 , respectively).
In order to assess the relevance of SCA11 mutations in European ADCA patients and to better understand resulting phenotypes, we have genotyped 148 index patients of ADCA families for TTBK2 mutations.
Material and Methods:
We selected 148 index patients from ADCA families negative for repeat expansions in SCA1, Informed consent was obtained from all patients participating in this study.
High resolution melting (HRM) curve analysis in 69 samples (Germany):
The Cerebral MRI showed cerebellar atrophy affecting essentially the vermis in both cases. The grand father of the index case also complained of gait instability starting at age 58 but was not available for genetic analysis.
In the index patient of the German SCA11 family ataxia started at age 44 when he experienced mild unsteadiness in the dark. He remained able to play tennis until age 53.
Examination revealed oculomotor disturbances with saccadic pursuit, gaze evoked nystagmus, dysmetric saccades and impaired optokinetic nystagmus. Cerebellar dysarthria was mild. Gait was ataxic with some problems in tandem walk and Romberg manoeuvre. There was no tremor and appendicular ataxia was more pronounced in the legs than in the arms. Despite some stiffness in walking and reduced arm swing there was no significant alteration in muscle tone or reflexes. Nerve conduction studies and sympathetic skin response were normal. MRI revealed pancerebellar atrophy. The mother developed gait ataxia between 40 and 50 years of age and died at age 76 after 5 years in a wheelchair. A brother and a sister of the mother as well as the maternal grandmother had a similar course of disease. Only the healthy 64 year old sister of the index patient was available for genetic analyses and showed to be negative for the
TTBK2-mutation.
There was no evidence for any genealogical link between both SCA11 families with both families originating from over more than 600 km apart from each other. Moreover, haplotype analysis showed only partial genotype identity that is not arguing for a recent common ancestor (data not shown).
A non-synonymous amino acid change in exon 13 T651M was detected in one German-Polish SCA patient but not present in the similarly affected brother and thus excluded this variant as a disease-causing sequence change. Two additional silent coding variants ( As in the British kindred 14 , the French and the German SCA11 families presented with rather pure cerebellar ataxia, cerebellar atrophy and normal life expectancy (ADCA type III according to Harding). The course of disease in our families revealed rather slow progression.
Patients were still able to play tennis up to 9 years with the disease and remained ambulant even 16 years after onset of ataxia. Only one patient became wheelchair dependent after more than 20 years with the disease.
Like most of the other SCA loci with point mutations SCA11 is rare 15;16 . In the SCA subtypes of ADCA III, non-dynamic SCA mutation included SCA5, 11 and 14. After excluding the probably more prevalent SCA14 17 , SCA5 and 11 screening should also be considered. The frequency of SCA11 in our highly selected study population is approximately one percent.
Considering only ADCA-III patients, with pure cerebellar symptoms, increased this figure (2 SCA11 index cases in 86 ADCA-III patients).
Although unlikely, we cannot exclude however, that we may have missed mutations because of the separate approaches in the French and German cohorts using direct sequencing and HRM, respectively. Nonetheless, both methods revealed a single heterozygous frameshift mutation (c.1306-1307delGA)in exon 12. As the 148 index patients included in this study derive from a total cohort of about 450 ADCA families after exclusion of all polyglutamine mutations (SCA1, 2, 3, 6, 7, and 17), and partly exclusion of SCA5, SCA13, SCA14, and SCA28, the frequency of SCA11 in an unselected ADCA cohort would be expected to be well below 1 percent.
Our finding of a recurrent frameshift mutation suggests, in accordance with the two TTBK2 mutations described before, that SCA11 is caused by haploinsufficiency of tau tubuline kinase 2. As up to now no experimental insights in the pathogenesis of SCA11 exit, transgenic models of SCA11 implementing the genetic evidence for pathogenic mutations in exons 11 to Tables   Table 1 Mutations Square symbols are men, the circles are women. The filled symbols are affected individuals.
The numbers are an internal reference for each sampled individual. Stars indicate sampled subjects.
